Business, energy, technology, markets and global industry news from Business News Today

Denali Therapeutics

PharmaDeviceNews Denali Therapeutics
Editorial infographic highlighting Spruce Biosciences’ MPS IIIB disease progression research, featuring neurological imagery, enzyme therapy molecular models and laboratory equipment, with key milestones for TA-ERT development, a planned FDA filing and a confirmatory clinical trial.
Pharma & Biotech

Can Spruce Biosciences prove its Sanfilippo treatment slows brain decline? New data could strengthen its FDA case

Spruce Biosciences prepares MPS IIIB disease progression data as TA-ERT approaches its FDA filing and confirmatory trial milestones.

Read More
A scientist reviews brain imaging and neurological research data as Denali Therapeutics channels its $195 million FDA voucher proceeds into blood-brain barrier drug development and the TransportVehicle pipeline. Representative image.
Pharma & Biotech

Denali monetises its FDA voucher as AVLAYAH enters a critical confirmatory phase

Denali Therapeutics is converting AVLAYAH’s regulatory reward into non-dilutive capital for its blood-brain barrier pipeline, but clinical and commercial risks remain.

Read More